Skip to main content
Publications
Quinn KL, Abdel-Qadir H, Barrett K, Bartsch E, Beaman A, Biering-Sorensen T, Colacci M, Cressman A, Detsky A, Gosset A, Lassen MH, Kandel C, Khaykin Y, Lapointe-Shaw L, Lovblom E, MacFadden DR, Perkins B, Rothman KJ, Skaarup KG, Stall N, Tang T, Yarnell C, Zipursky J, Warkentin MT, Fralick M, COVID-ACE Group. Variation in the risk of death due to COVID-19: an international multicenter cohort study of hospitalized adults. J Hosp Med. 2022 Oct 1;17(10):739-802. doi: 10.1002/jhm.12946
Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097